Herceptin biosimilar bandwagon gathers weight with new filing

1 August 2017
biosimilars_samples_large

Following news last month that a US Food and Drug Administration (FDA) advisory panel had given its backing to a biosimilar version of Swiss pharma giant Roche’s (ROG: SIX) big-selling cancer drug Herceptin (trastuzumab), a separate copycat version has moved closer to market.

During its meeting in July, the agency’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously to recommend approval of a Herceptin biosimilar developed Netherlands-incorporated Mylan (Nasdaq: MYL) and India’s Biocon (BSE: 532523).

Now Roche will note that US biotech Amgen (Nasdaq: AMGN) and Ireland-incorporated drugmaker Allergan (NYSE: AGN) have submitted a Biologics License Application (BLA) to the FDA for ABP 980, a biosimilar candidate referencing the same drug.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars